79 citations
,
November 2016 in “EMBO Reports” Disruptions in mammary stem cell division can lead to cancer, but targeting these processes might help treat breast cancer.
June 2025 in “BMJ Case Reports” Axitinib treatment turned a man's grey hair back to black.
1 citations
,
November 2024 in “Neuro-Oncology” Temozolomide can cause severe bone marrow suppression, leading to life-threatening complications.
May 2015 in “Cancer research” After chemotherapy for early breast cancer, 33.4% of patients had long-term significant hair loss, with some hair regrowth over time, but treatments for hair loss were largely ineffective.
3 citations
,
August 2013 in “Journal of the National Cancer Institute” The number of advanced breast cancer cases in women under 40 has increased, but the overall numbers are still low.
12 citations
,
September 2015 in “Drug Design Development and Therapy” AD198 is more effective than doxorubicin in stopping certain dog cancer cells.
81 citations
,
February 2000 in “Anti-cancer drugs” Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.
20 citations
,
March 1975 in “Journal of steroid biochemistry/Journal of Steroid Biochemistry” The study concludes that a genetic mutation in TFM mice leads to reduced androgen receptor activity, affecting the body's response to male hormones.
March 2024 in “BMC cancer” High levels of ST14 and TMEFF1 proteins in ovarian cancer are linked to worse patient outcomes and may be a new treatment target.
3 citations
,
February 2005 in “Lung Cancer” The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.
April 2020 in “Journal of the Endocrine Society” A rare ovarian tumor caused high male hormone levels, but surgery fixed it.
36 citations
,
October 2016 in “Bone” A male with aromatase deficiency improved bone health with estradiol treatment.
1 citations
,
January 2016 in “Journal of Clinical & Experimental Dermatology Research”
Some side effects of breast cancer chemotherapy last longer than others, and patient feedback can help improve care.
19 citations
,
July 2019 in “Journal of Endocrinology” GTx-024 and Danazol affect the uterus like DHT, while GTx-007 has little impact.
April 2019 in “Journal of the Endocrine Society” Rapid virilization should be checked for possible ovarian or adrenal cancer.
Skin cells can naturally limit the growth of cancerous changes by balancing cell renewal and differentiation.
January 2020 in “Mastology” Flow cytometry was effective in diagnosing metastatic breast cancer in a bone marrow sample.
December 2025 in “Drug Design Development and Therapy” Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.
October 2024 in “Journal of the Endocrine Society” Rare ovarian tumors can cause hyperandrogenism, even if imaging appears normal.
January 2024 in “Wiadomości Lekarskie” Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.
5 citations
,
March 2020 in “Thoracic Cancer” CT-707 is effective and safe for treating certain Chinese lung cancer patients.
2 citations
,
September 2018 in “JAAD case reports” A rare type of skin cancer with mucosal involvement was partially treated but eventually relapsed.
3 citations
,
January 2017 in “Revista chilena de nutrición” Certain natural compounds called terpenes may help prevent prostate cancer.
October 2024 in “Journal of the Endocrine Society” Bilateral salpingo-oophorectomy resolved hyperandrogenism in a postmenopausal woman with rare ovarian tumors.
April 2016 in “Journal of Investigative Dermatology” SOX4 is crucial for the development of melanoma.
13 citations
,
June 2008 in “International Journal of Dermatology” Sorafenib can cause a unique skin reaction.
46 citations
,
October 2018 in “JCI insight” CD8+ T cells are involved in alopecia areata and may cause disease relapse.
March 2014 in “The Journal of Urology” Finasteride increases CD8+ T cells in BPH tissues.
16 citations
,
May 2020 in “Frontiers in pharmacology” Minoxidil can stop the growth of ovarian cancer cells without harming the heart.